Monte Rosa Therapeutics (GLUE) Expected to Announce Quarterly Earnings on Thursday

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) is expected to be announcing its Q1 2025 earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $13.57 million for the quarter.

Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.60. The business had revenue of $14.00 million during the quarter, compared to analyst estimates of $43.73 million. On average, analysts expect Monte Rosa Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Monte Rosa Therapeutics Trading Up 1.4 %

GLUE stock traded up $0.07 during midday trading on Friday, hitting $4.97. 365,800 shares of the company's stock were exchanged, compared to its average volume of 1,056,061. Monte Rosa Therapeutics has a 1-year low of $3.21 and a 1-year high of $12.40. The stock has a market capitalization of $305.70 million, a PE ratio of -2.72 and a beta of 1.53. The business has a 50-day simple moving average of $5.20 and a two-hundred day simple moving average of $6.57.

Insider Buying and Selling

In other Monte Rosa Therapeutics news, Director Chandra P. Leo purchased 10,000 shares of the business's stock in a transaction on Monday, March 24th. The shares were bought at an average cost of $5.84 per share, for a total transaction of $58,400.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company's stock, valued at approximately $58,400. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.50% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Wells Fargo & Company reduced their price objective on shares of Monte Rosa Therapeutics from $11.00 to $10.00 and set an "equal weight" rating on the stock in a report on Friday, March 21st. Wedbush reiterated an "outperform" rating and set a $17.00 price target (up from $15.00) on shares of Monte Rosa Therapeutics in a research report on Thursday, March 20th. Finally, Lifesci Capital assumed coverage on shares of Monte Rosa Therapeutics in a report on Wednesday, March 12th. They issued an "outperform" rating and a $19.00 price objective on the stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.